Principal Investigator of the TLC-ART Program, Professor in the Department of Pharmaceutics
Phone: 206-543-9434
Email: rodneyho@uw.edu
Rodney Ho, PhD, NAI, FAAAS. FAAPS is a professor and presidential entrepreneurial fellow of the University of Washington and holds appointments at the Fred Hutchinson Cancer Research Center. Professor Ho is the founding Executive Director of the Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH, a NIH-designated National Hub). He has served in a number of leadership roles including Assoc Dean for Research and New Initiatives. His current TLC-ART, Targeted, Long-acting, and Combination Therapeutic Program, built on a collaborative basic and translational research team composed of scientists, physicians, students, and post-doc, focuses on developing targeted, drug-combination and long-acting therapeutics for HIV/AIDS and cancer. Dr. Ho serves as the Co-Director of the Institute for Translational Health Sciences ITHS Regulatory Knowledge and Support Team.
Dr. Ho is a distinguished leader in pharmaceutical sciences and systems pharmacology with a proven track record of innovation in long-acting and targeted drug combination therapies for AIDS and Cancer. He serves on a number of national and international initiatives relating to Cancer and HIV therapeutics including LEAP leadership team to facilitate the development of long-acting therapies for NIH and WHO’s Unitaid. He is an expert on pharmacology and systems approaches to drug targeting and long-acting therapy. His research aims to improve the therapeutic efficacy and safety of viral and cancer drugs, medical diagnostic agents, and vaccines. He is an elected member of the National Academy of Innovators, and an elected fellow of the American Association for the Advancement of Science (AAAS) and the American Association of Pharmaceutical Scientists (AAPS). He is an appointed National Cancer Institute’s Council Member of the NIH.